NL0C-015A Exhibited Anti-NSCLC Activities via Modulation of Hippo- YAP1, EGFR-MEK, and NF-κB-TOR Pathways in NSCLC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.